Cell-Based Models for Development of Antiatherosclerotic Therapies

Table 2

The comparative data from clinical trials on carotid atherosclerosis regression.

Trial	Medication	⁢Mean annual IMT change, mm		Reference
		Placebo	Treatment
PLAC II	Pravastatin	0.068	0.059	Crouse III et al., 1995 [45]
KAPS	Pravastatin	0.029	0.010	J. T. Salonen and R. Salonen, 1993 [46]
ASAP	Simvastatin	—	−0.009	Smilde et al., 2001 [47]
PREVENT	Amlodipine	0.011	−0.015	Pitt et al., 2000 [48]
ASAP	Atorvastatin	—	−0.020	Smilde et al., 2001 [47]
CLAS	Colestipol, niacin	0.010	−0.020	Blankenhorn et al., 1993; Hodis, 1995 [49, 50]
MARS	Lovastatin	0.015	−0.028	Blankenhorn et al., 1993; Hodis, 1995 [49, 51]
VHAS	Verapamil	—	−0.028	Zanchetti et al., 1998 [52]
AMAR	Allicor	0.015	−0.022	Orekhov et al., 2013 [8]
NCT01743404	Inflaminat	0.062	−0.068	Orekhov et al., 2013 [8]
NCT01742000	Karinat	0.111	0.006	Orekhov et al., 2013 [8]